David Fermin

1.9k total citations · 1 hit paper
19 papers, 345 citations indexed

About

David Fermin is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Biomedical Engineering. According to data from OpenAlex, David Fermin has authored 19 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Cardiology and Cardiovascular Medicine, 10 papers in Surgery and 7 papers in Biomedical Engineering. Recurrent topics in David Fermin's work include Cardiomyopathy and Myosin Studies (10 papers), Cardiac Structural Anomalies and Repair (9 papers) and Mechanical Circulatory Support Devices (7 papers). David Fermin is often cited by papers focused on Cardiomyopathy and Myosin Studies (10 papers), Cardiac Structural Anomalies and Repair (9 papers) and Mechanical Circulatory Support Devices (7 papers). David Fermin collaborates with scholars based in United States, Italy and Germany. David Fermin's co-authors include Jennifer L. Hall, Leslie W. Miller, Suzanne Grindle, Hideo A. Baba, Paul J.R. Barton, Jeremias Wohlschlaeger, Peter Eckman, Emma J. Birks, Mark S. Slaughter and Soon Park and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and American Journal of Transplantation.

In The Last Decade

David Fermin

15 papers receiving 340 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

2024 34 citations Florian Rader, Artur Oręziak et al. JACC Heart Failure profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Fermin United States	8	195	151	121	96	30	19	345
B. Cabuay United States	8	152 0.8×	100 0.7×	76 0.6×	116 1.2×	12 0.4×	12	273
J. Stypmann Germany	9	179 0.9×	127 0.8×	71 0.6×	115 1.2×	9 0.3×	23	319
Priyanthi Dias United Kingdom	6	187 1.0×	88 0.6×	38 0.3×	132 1.4×	6 0.2×	21	293
Stephanie J. Nakano United States	12	198 1.0×	99 0.7×	61 0.5×	138 1.4×	6 0.2×	28	356
Arthur Preovolos Australia	11	288 1.5×	243 1.6×	262 2.2×	253 2.6×	16 0.5×	12	614
José Gavara Spain	10	270 1.4×	119 0.8×	63 0.5×	66 0.7×	3 0.1×	59	426
Guangqi Qin Sweden	10	34 0.2×	172 1.1×	102 0.8×	36 0.4×	17 0.6×	17	271
Arnaud Gay France	7	56 0.3×	149 1.0×	45 0.4×	83 0.9×	5 0.2×	12	270
Nima Aghili United States	11	90 0.5×	272 1.8×	249 2.1×	42 0.4×	4 0.1×	20	384
Yifei Huang Australia	10	97 0.5×	77 0.5×	49 0.4×	32 0.3×	7 0.2×	13	169

Countries citing papers authored by David Fermin

Since Specialization

Citations

This map shows the geographic impact of David Fermin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Fermin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Fermin more than expected).

Fields of papers citing papers by David Fermin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Fermin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Fermin. The network helps show where David Fermin may publish in the future.

Co-authorship network of co-authors of David Fermin

This figure shows the co-authorship network connecting the top 25 collaborators of David Fermin. A scholar is included among the top collaborators of David Fermin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Fermin. David Fermin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Desai, Milind Y., Sara Saberi, Jeffrey B. Geske, et al.. (2025). Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex. JACC Heart Failure. 13(6). 1037–1040. 2 indexed citations

Desai, Milind Y., Kathy Wolski, Jeffrey B. Geske, et al.. (2025). Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks. JACC. Cardiovascular imaging. 18(12). 1300–1311.

Desai, Milind Y., Kathy Wolski, Anjali Owens, et al.. (2024). Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM. Circulation. 151(19). 1378–1390. 14 indexed citations

Rader, Florian, Artur Oręziak, Lubna Choudhury, et al.. (2024). Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure. 12(1). 164–177. 34 indexed citations breakdown →

Shrestha, Nabin K., Richard McNamara, Wissam Abdallah, et al.. (2024). Ventricular late gadolinium enhancement by cardiac MRI as a predictor of atrial fibrillation in hypertrophic cardiomyopathy. International Journal of Cardiology. 411. 132263–132263. 3 indexed citations

Gauri, Andre, et al.. (2024). SEVERE HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY PRESENTING WITH APICAL BALLOONING - A RAPIDLY REVERSIBLE CAUSE OF CARDIOGENIC SHOCK. Journal of the American College of Cardiology. 83(13). 3586–3586.

Abdallah, Wissam, et al.. (2023). Abstract 16249: A Case of Myocarditis and Pneumonitis Associated With Pembrolizumab Therapy. Circulation. 148(Suppl_1).

Loyaga‐Rendon, Renzo Y., et al.. (2022). Predicting Short-Term Mortality in ECMO-Supported Patients Secondary to Decompensated Heart Failure and Acute Myocardial Infarction Using Machine Learning. The Journal of Heart and Lung Transplantation. 41(4). S470–S471. 3 indexed citations

Fermin, David, Sara Saberi, Theodore P. Abraham, et al.. (2022). Abstract 12690: Mavacamten Treatment in Patients With Obstructive and Nonobstructive Hypertrophic Cardiomyopathy: A Pooled Safety Analysis of 5 Clinical Trials. Circulation. 146(Suppl_1).

10.

Rader, Florian, Lubna Choudhury, Sara Saberi, et al.. (2021). LONG-TERM SAFETY OF MAVACAMTEN IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: INTERIM RESULTS OF THE MAVA-LONG TERM EXTENSION (LTE) STUDY. Journal of the American College of Cardiology. 77(18). 532–532. 25 indexed citations

11.

Loyaga‐Rendon, Renzo Y., David Fermin, Sangjin Lee, et al.. (2020). Changes in heart transplant waitlist and posttransplant outcomes in patients with restrictive and hypertrophic cardiomyopathy with the new heart transplant allocation system. American Journal of Transplantation. 21(3). 1255–1262. 14 indexed citations

12.

Leacche, Marzia, Theodore Boeve, M. Berner, et al.. (2020). Changing Landscape of Heart Transplantation in the US after Implementation of the New Allocation System: A UNOS Data Registry Analysis. The Journal of Heart and Lung Transplantation. 39(4). S75–S75. 1 indexed citations

13.

Huang, Sihong, et al.. (2020). The Pregnancy Heart Team Approach for the Adult with Hypertrophic Cardiomyopathy and Severe Left Ventricular Outflow Tract Obstruction. Maternal-Fetal Medicine. 3(1). 71–74. 1 indexed citations

14.

Fermin, David, Stephen D. Cohle, Paul Twydell, & Michael G. Dickinson. (2019). Early Recurrence of Myocardial Transthyretin Amyloid Deposition Three Years Post Heart Transplantation for Hereditary V40I Amyloidosis. Journal of Cardiac Failure. 25(8). S170–S170. 3 indexed citations

15.

Loyaga‐Rendon, Renzo Y., et al.. (2017). Prevention and Treatment of Thrombotic and Hemorrhagic Complications in Patients Supported by Continuous-Flow Left Ventricular Assist Devices. Current Heart Failure Reports. 14(6). 465–477. 7 indexed citations

16.

Hall, Jennifer L., David Fermin, Emma J. Birks, et al.. (2011). Clinical, Molecular, and Genomic Changes in Response to a Left Ventricular Assist Device. Journal of the American College of Cardiology. 57(6). 641–652. 80 indexed citations

17.

Fermin, David, Ana Barac, Sean P. Polster, et al.. (2008). Sex and Age Dimorphism of Myocardial Gene Expression in Nonischemic Human Heart Failure. Circulation Cardiovascular Genetics. 1(2). 117–125. 40 indexed citations

18.

Hall, Jennifer L., Suzanne Grindle, David Fermin, et al.. (2004). Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiological Genomics. 17(3). 283–291. 90 indexed citations

19.

Huebert, Robert C., Qinglu Li, Neeta Adhikari, et al.. (2004). Identification and regulation of Sprouty1, a negative inhibitor of the ERK cascade, in the human heart. Physiological Genomics. 18(3). 284–289. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact